146 related articles for article (PubMed ID: 11774835)
21. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Naing C; Poovorawan Y; Tong KS
BMC Infect Dis; 2018 Nov; 18(1):564. PubMed ID: 30428847
[TBL] [Abstract][Full Text] [Related]
23. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
Mutimer D
J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
[No Abstract] [Full Text] [Related]
24. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
25. Hepatitis B virus resistance to antivirals: clinical implications and management.
Zoulim F
J Hepatol; 2003; 39 Suppl 1():S133-8. PubMed ID: 14708691
[No Abstract] [Full Text] [Related]
26. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
27. [Lamivudine treatment: realities and expectations].
Crespo J; Pons-Romero F
Gastroenterol Hepatol; 1997 Oct; 20(8):422-5. PubMed ID: 9410542
[No Abstract] [Full Text] [Related]
28. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
Gelinck LB; Claas EC; Kroon FP
J Hepatol; 2005 Aug; 43(2):360-1; author reply 361. PubMed ID: 15970350
[No Abstract] [Full Text] [Related]
29. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
Puoti M; Cozzi-Lepri A; Ancarani F; Bruno R; Ambu S; Ferraro T; Tundo P; Santantonio T; Toti M; Bonasso M; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):811-7. PubMed ID: 15535419
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of lamivudine resistance by HBV.
Schalm SW
Lancet; 1997 Jan; 349(9044):3-4. PubMed ID: 8988109
[No Abstract] [Full Text] [Related]
31. Viral hepatitis B.
Lai CL; Ratziu V; Yuen MF; Poynard T
Lancet; 2003 Dec; 362(9401):2089-94. PubMed ID: 14697813
[TBL] [Abstract][Full Text] [Related]
32. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
33. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B immune reconstitution syndrome in a patient with HIV infection.
John MA; Gosnell BI; Manzini TC; Ramdial P; Moosa MS
Int J STD AIDS; 2016 Oct; 27(12):1126-1129. PubMed ID: 26769756
[TBL] [Abstract][Full Text] [Related]
35. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.
Bonacini M; Kurz A; Locarnini S; Ayres A; Gibbs C
Gastroenterology; 2002 Jan; 122(1):244-5. PubMed ID: 11806370
[No Abstract] [Full Text] [Related]
36. [Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
Rey D; Fritsch S; Schmitt C; Partisani M; Kempf-Durepaire G; Nicolle M; Krantz V; De Mautort E; Stoll-Keller F; Lang JM
Gastroenterol Clin Biol; 2000 Jan; 24(1):125-7. PubMed ID: 10679599
[TBL] [Abstract][Full Text] [Related]
37. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
Kumashiro R; Kuwahara R; Ide T; Koga Y; Arinaga T; Hisamochi A; Ogata K; Tanaka K; Sata M
Intervirology; 2003; 46(6):350-4. PubMed ID: 14688451
[TBL] [Abstract][Full Text] [Related]
38. Lamivudine for chronic hepatitis B and HIV co-infection.
Carton JA; Maradona JA; Asensi V; RodrÃguez M; MartÃnez A
AIDS; 1999 May; 13(8):1002-3. PubMed ID: 10371189
[No Abstract] [Full Text] [Related]
39. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Wang J; Liu J; Qi C; Yan T; Cao F; Jin L; He Y; Yang Y; Zhang S; Chen T; Zhao Y
Antivir Ther; 2015; 20(7):681-7. PubMed ID: 26215771
[TBL] [Abstract][Full Text] [Related]
40. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
